Table 3. ESPRIT, SMART and SILCAAT hazard ratios associated with baseline biomarkers [per one log₂ (i.e. doubling) increment] cohort: all control patients.

	Any cancer						Infection-related cancersa						Infection-unrelated cancers
	CRP		D-dimer		IL-6		CRP		D-dimer		IL-6		CRP		D-dimer		IL-6
	HR(95%CI)*	P	HR (95% CI)*	P	HR(95%CI)*	P	HR (95% CI)*	P	HR(95%CI)*	P	HR (95% CI)*	P	HR (95% CI)*	P	HR(95%CI)*	P	HR(95%CI)*	Pe
Model 1b	1.21 (1.11–1.32)	<0.001	1.25 (1.10–1.43)	<0.001	1.48 (1.30–1.69)	<0.001	1.22 (1.07–1.39)	0.003	1.25 (1.01–1.54)	0.04	1.49 (1.21–1.84)	<0.001	1.20 (1.08–1.34)	<0.001	1.26 (1.06; 1.49)	0.007	1.47 (1.24; 1.74)	<0.001
Model 2c	1.16 (1.06–1.26)	0.001	1.17 (1.01–1.35)	0.03	1.38 (1.19–1.59)	<0.001	1.18(1.03–1.35)	0.02	1.19 (0.95–1.50)	0.13	1.42 (1.14–1.78)	0.002	1.15 (1.02–1.28)	0.02	1.15 (0.96; 1.38)	0.12	1.35 (1.12; 1.63)	0.002
Model 3d	1.06 (0.96–1.17)	0.22	1.06 (0.91–1.23)	0.43	1.29 (1.09–1.52)	0.003	1.08 (0.92–1.26)	0.34	1.06 (0.83–1.36)	0.64	1.32 (1.01–1.71)	0.04	1.06 (0.93–1.20)	0.40	1.06 (0.88; 1.28)	0.53	1.27 (1.02; 1.58)	0.03
No. of patientse	5022		5006		4994		5022		5006		4994		5022		5006		4994
No. of eventse	172		171		171		70		70		70		102		101		101

CI, confidence interval; CRP, C-reactive protein; HR, hazard ratio; IL-6, interleukin-6.

^aAll AIDS-defining-malignancies along with vagina, vulva, penis, anal and oral cavity/pharynx cancers; Hodgkin lymphoma; liver and stomach cancer. All other malignancies were considered to be infection-unrelated cancers.

^bStratified for study and unadjusted.

^cStratified for study and adjusted for demographics (age, race, sex and continent), and study entry and time-updated CD4⁺ cell counts.

^dAs in model 2 and also adjusted for all biomarkers.

^eDue to missing data, numbers are reduced in model containing all biomarkers to 4982 participants with 171 any cancer, 70 infection-related cancer and 101 infection-unrelated cancer events.

^*HR, hazard ratio for one log₂ (i.e. doubling) increase in indicated biomarker.